Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Stoke Therapeutics, Inc.
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 18, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
June 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 06, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 08, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
December 01, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
November 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 17, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
September 20, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
September 05, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
July 25, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
July 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 04, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
May 03, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.